President Trump’s administration has made the decision not to cover highly-popular obesity treatments under the 2026 Medicare ...

New evidence suggests that factors other than the percentage of weight loss should be considered when determining the success ...

Those in favor of the classification argue that excess fat accumulation/distribution is linked to sustained and serious ...

New York’s reputation as a trailblazer for health equity is in danger. We must ensure equity in obesity treatment.

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

New research to be presented at the European Congress on Obesity (ECO 2025) suggests that focusing on percentage weight loss ...

Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in ...

Rhythm's Phase 3 trial shows setmelanotide significantly reduced BMI in rare hypothalamic obesity without new safety concerns over 52 weeks.

A new medical database automatically compiles the medical records of obese patients and those suffering from obesity-related diseases in a uniquely comprehensive and reliable manner.